Droperidol
Butyrophenone Derivatives
- Drug class
- Butyrophenone Derivatives
- Availability
- Prescription only
- Routes
- Intramuscular, Intravenous
- Markets covered
- 2
- Products on record
- 3
- FDA reports (12 mo)
- 102
Overview
Plain-language summary, compiled from the cited regulatory records
Droperidol is a medication belonging to the butyrophenone derivative class of drugs [1]. It is approved for use in reducing the incidence of nausea and vomiting that can occur with surgical and diagnostic procedures [1].
In the past 12 months, there have been 102 adverse event reports associated with droperidol [2]. Common adverse events reported include acute kidney injury, anuria, constipation, hepatic cytolysis, and urinary retention [2].
Droperidol is available under various brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | May 15, 2026 |
| US United States | FDA | 1 | March 20, 2023 |
GBUnited Kingdom· MHRA
2 products
Uses
Prevention and treatment of post-operative nausea and vomiting (PONV) in adults and, as second line, in children (2 to 11 years) and adolescents (12 to 18 years). Prevention of nausea and vomiting induced by morphine and derivatives during post- operative patient controlled analgesia (PCA) in adults.
4.
How to take
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
Droperidol Injection is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures.
How to take
Drug interactions
Known interactions involving Droperidol. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 493. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL154130072 · revised May 15, 2026
- [2]FDA DailyMed · 147e033d-d997-4e… · revised March 20, 2023 [PDF]
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.